Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine


ABSTRACT

In patients with major depressive disorder or bipolar disorder, abnormalities in excitatory and/or inhibitory neurotransmission and neuronal plasticity may lead to aberrant functional connectivity patterns within large brain networks. Network dysfunction in association with altered brain levels of glutamate and gamma-aminobutyric acid have been identified in both animal and human studies of depression. In addition, evidence of an antidepressant response to subanesthetic-dose ketamine has led to a collection of studies that have examined neurochemical (e.g., glutamatergic and gamma-aminobutyric acidergic) and functional imaging correlates associated with such an effect. Results from these studies suggest that an antidepressant response in association with ketamine occurs, in part, by reversing these neurochemical/physiological disturbances. Future studies in depression will require a combination of neuroimaging approaches from which more biologically homogeneous subgroups can be identified, particularly with respect to treatment response biomarkers of glutamatergic modulation.

Keywords: Bipolar disorder, Glutamate, Ketamine, Major depressive disorder, Mood disorder, NMDA receptor antagonist

http://dx.doi.org/10.1016/j.biopsych.2016.05.005

In rodent studies, pharmacologic- and stress-induction paradigms that lead to depressive-like behaviors have been associated with alterations in cortical glutamate (Glu) findings that have been reversed by monoaminergic antidepressants and electroconvulsive therapy (4,5). As a result, a glutamatergic hypothesis of depression was posited that extends beyond monoaminergic dysfunction in patients with major depressive disorder (MDD) or bipolar disorder (BD) (6). Interestingly, clinical studies of depression using magnetic resonance spectroscopy (MRS) and positron emission tomography (PET) have identified alterations in Glu and gamma-aminobutyric acid (GABA) concentrations and activity, suggesting that dysfunction in excitatory and/or inhibitory neurotransmitter signaling mechanisms may play a critical role in depression. In this review, we examine studies that use electroencephalography (EEG), magnetoencephalography (MEG), and functional magnetic resonance imaging (fMRI) techniques to identify aberrant functional neural circuitry patterns in patients with MDD and BD. We then hypothesize links between neurotransmitter abnormalities and functional neurocircuitry deficits in depression, from which we encourage future work using MRS or PET techniques in conjunction with functional imaging techniques to elucidate and characterize these relations.

Furthermore, a pivotal role of glutamatergic neurotransmission in the pathophysiology of and treatment response in MDD and BD has been supported by studies that demonstrate antidepressant efficacy of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine (7) in preclinical and clinical studies (8,9). Here, we highlight ketamine as the best available molecular tool with which to probe the impact of glutamatergic modulation on excitatory/inhibitory neural circuitry dynamics in healthy and depressed subjects with MDD or BD owing to evidence supporting ketamine’s efficacy and its lower burden of side effects compared with other glutamatergic modulating agents (9–14). Within this framework, we review clinical studies using MRS, PET, fMRI, and MEG to explore how glutamatergic modulation may alleviate aberrant functional neurocircuitry in depression and mediate antidepressant response to ketamine. Finally, we emphasize the importance of using a combinatorial approach to better identify and predict treatment responders to ketamine.

DYSREGULATION OF GLUTAMATERGIC AND GABAERGIC NEUROTTRANSMISSION IN DEPRESSION

Proton MRS (1H-MRS) is an in vivo imaging technique for total tissue detection of neurochemicals, including N-acetylaspartate, GABA, Glu, glutamine (Gln), and a combination of Glu/Gln with a
Glutamate and GABA in Depression

In comparison with healthy subjects, aberrant amino acid neurotransmitter levels measured by $^1$H-MRS have been found in individuals with MDD (6,17–19) and BD (20,21). Specifically, in patients with MDD, Glu and Glx reductions were found in the dorsolateral prefrontal cortex (PFC) (22) and other PFC areas such as the dorsomedial and dorsoanterolateral PFC (23) and anterior cingulate cortex (ACC) (24), with increased levels in the occipital cortex (OCC) (25) to a degree that may be related to duration of illness (26). In a meta-analysis of 17 $^1$H-MRS studies of patients with MDD, reductions of Glx in the PFC were associated with number of failed antidepressant treatments, a measure of chronicity and a proxy for severity of depressive illness course (19). Surprisingly, this study found no isolated reductions in Glu, implicating astrocyte-mediated metabolic alterations in Glu metabolism underlying the pathophysiology of MDD (19). A possible explanation may be related to abnormal mitochondrial energy production in glutamatergic neurons. In an in vivo $^{13}$C-MRS and $^1$H-MRS study that examined the potential relation between the Glu/Gln cycle and mitochondrial energy production (27), patients with MDD showed a 26% reduction in mitochondrial energy production compared with healthy subjects, although no differences were

...
found in Glu/Gln cycle rate. The investigators suggested that reductions in energy production within glutamatergic neurons resulted from reduced synaptic strength by reductions in AMPA or NMDA receptors in the postsynaptic neuron. In addition, although the study was performed post hoc without correction for multiple comparisons, the investigators found a negative association between Glu concentrations and the number of depressive episodes (27), suggesting that reductions in synaptic strength may reduce Glu neurotransmission over successive episodes of depression.

Neurochemical studies in patients with BD have shown mixed results. Although some studies found no differences in Glu between patients with BD and healthy subjects (28–31), two meta-analyses of 1H-MRS studies in BD noted increased G1x in the PFC regardless of mood state, as well as in the ACC in depressed states (20,32). A recent study showed that elevated Glu in the ACC associated with patients with BD in euthymic states was related to number of depressive/manic episodes (21); notably, this finding may allow for differentiation of depression between BD and MDD. Impaired oxidative metabolism in glutamatergic neurons has been hypothesized to explain elevated G1x and lactate levels associated with mixed or depressed states in BD (33) and further supports a contributory role of inflammation in the pathophysiology of depression (34). Wide and overlapping ranges of mood and neurocognitive states in BD (35) increase variation within and between study samples, contributing to challenges in interpreting neurochemical and functional imaging studies of BD. Therefore, further studies of BD may require a larger number of patients to better examine state- versus trait-related brain correlates in addition to the development of novel and sophisticated models of BD subphenotypes (36). Finally, in addition to known sources of heterogeneity between 1H-MRS studies of depression (37), such as subject selection, field strength, MRS sequences, and anatomic placement of the voxel of interest (18), studies of patients with BD are further confounded by concurrent use of medications (e.g., valproate and lithium), which has been shown to alter Glu and GABA levels in the brain (20,38). Unsurprisingly, 1H-MRS studies in MDD have consistently shown reduced levels of Glu, Gln, G1x, and GABA (39), whereas in BD studies, elevated levels of Glu have been observed inconsistently without differences in Gln, G1x, or GABA (20).

Detection and quantification of neurotransmitter receptors using PET imaging, in conjunction with administration of a radioactive ligand that is displaced by the endogenous neurotransmitter of interest at its receptor, provides complementary information to MRS studies regarding neurotransmitter signaling mechanisms. For example, reduced mGluR5 (Figure 1) density in patients with MDD was observed in two clinical PET studies that used an mGluR5-specific radioligand (40,41). Taken together with animal studies showing antidepressant-like effects associated with the mGluR5-specific antagonists 2-methyl-6-(phenylethynyl)-pyridine and 3-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (42–44), these findings suggest that abnormal mGluR5 signaling may be involved in the pathophysiology of depression. One of the studies was of patients aged 55 to 80 years (40) and may be confounded by comorbid medical conditions, their treatment, and age-related brain changes. Nevertheless, a clear need exists to develop specific Glu receptor ligands for mGluRs and ionotropic Glu receptor subunits (45) to better understand abnormal glutamatergic neurotransmission and plasticity in depression.

Studies of inhibitory neurotransmitter systems in depression have also obtained mixed results. In 1H-MRS studies of patients with MDD, lower GABA levels were reported in the PFC (23), ACC (37), and OCC (46) compared with healthy subjects, and these changes may be more pronounced in association with melancholia (25). One negative study found no group differences in GABA concentrations in patients with remitted MDD (47), but the investigators suggested that GABA concentrations (and activity) may be sensitive to the presence of a depressive episode. Moreover, a 1H-MRS study of patients with MDD found no group differences in G1x concentrations within the ventromedial PFC compared with healthy subjects, but observed an increased ratio of G1x to GABA associated with lower age of depression onset, suggesting that an increased excitatory/inhibitory neurotransmitter ratio may be associated with depression vulnerability (47). In studies of euthymic patients with BD, decreased (48) and increased (49) GABA levels have been observed compared with healthy subjects, as have no differences in GABA levels (50).

From the hypothesized excitatory/inhibitory imbalance in depression (51), 1H-MRS studies of Glu and Glu/GABA ratios suggest that a deficiency of excitatory neurotransmission or an imbalance of excitatory/inhibitory neurotransmission characterizes a subset of depressed patients. Despite the clinical efficacy of GABAergic medications (e.g., valproic acid, lamotrigine, and carbamazepine) in BD (52,53), inconsistent reports of GABA levels associated with BD do not support an isolated deficiency in GABA in depression. Abnormalities in glutamatergic neuronal metabolism may be experienced in a proximal stage of the underlying pathophysiology of MDD and BD. For example, in a study of patients with schizophrenia randomly assigned to receive pomaglumetad (a metabotropic Glu 2/3 receptor agonist) versus placebo for 6 weeks, greater improvement in symptoms was experienced earlier in the course of illness or with history of a medication targeted at the dopamine D2 receptor (54). Future prospective investigations in larger clinical samples may allow identification of subgroups of depressed patients who better respond to GABA- or Glu-modulating therapies along the illness course. Moreover, innovations to current MRS techniques (27), such as application of novel pulse sequences at higher magnetic field strengths (e.g., 7T) that can better resolve cerebral Glu, Gln, and GABA concentrations (55), could facilitate identification of biologically homogeneous and enriched subgroups (39) to which directed clinical interventions can be addressed (56).

FUNCTIONAL CIRCUITRY ABNORMALITIES IN DEPRESSION

Neural circuitry describes the complex array of interconnected neurons in the brain from which simultaneous and coordinated information processing is refined and reorganized by experience-related synaptic changes (57). Neuroimaging methods that indirectly (e.g., fMRI blood-oxygen level dependent [BOLD] signal) or directly (e.g., EEG and MEG) examine neural activity aim to identify circuitry-level
abnormalities and/or response to behavioral or neurochemical interventions (17). Considerations are necessary to address before links can be drawn between amino acid neurochemistry and functional imaging. First, MEG possesses greater spatial resolution than EEG (58,59); thus, we focus primarily on MEG studies. Second, although functional neuroimaging can be used in conjunction with cognitive and/or emotionally salient tasks, we focus on studies performed at resting state (task-free) from which functional connectivity patterns are derived as EEG and MEG frequency findings are reviewed in further detail. Third, functional connectivity patterns within larger interconnected neural circuits have emerged from novel statistical techniques (60,61). Finally, we examine studies of abnormal functional connectivity networks as they may relate to neurochemical studies of Glu and GABA in depression.

Abnormalities in resting-state functional connectivity patterns in patients with MDD have been found within and between large brain networks. The default mode network (DMN), which includes the medial PFC (mPFC) and posterior cingulate cortex, has been shown to deactivate during cognitive tasks and is associated with introspection or self-referential thought when not actively recruited in task performance (62). The DMN and other networks involved in cognitive control of attention and emotion have been shown to differ in patients with MDD compared with healthy controls (63). In MDD, reduced connectivity has been shown in frontoparietal brain networks, and hyperconnectivity (increased positive or reduced negative connectivity) has been shown within the DMN and between the subgenual ACC (sgACC) and mPFC (63), regions that have been linked to abnormalities in GABA in animal models (64,65), as well as GABA reductions (66) and Glx/GABA imbalances (47) in patients with MDD.

In a systematic review of eight resting-state fMRI studies of patients with BD in all mood states, abnormalities in functional connectivity were found in the mPFC and ACC with limbic-striatal regions (67). Compared with MDD patients, BD patients show significantly stronger functional connectivity within the dorsolateral PFC and ventrolateral PFC, as well as inferior frontal/dorsolateral PFC to ACC (68), suggesting that changes in functional connectivity between the ACC and PFC, as well as differences in Glu neurotransmission within the ACC, may differentiate the two disorders. This is supported by studies that compared BD and MDD patients and found differences in PFC activation during emotionally laden tasks (69).

Similarities between functional connectivity patterns derived from resting-state fMRI studies and MEG studies across multiple frequency bands were demonstrated in healthy subjects using a model-free independent component analysis (70–72). With the use of a similar model on beta band-filtered MEG data (73), our group identified decreased connectivity between the sgACC and a network within the precentral motor cortex and precuneus and increased connectivity in limbic areas (i.e., amygdala and temporal cortex) in patients with MDD compared with healthy subjects. These results support the role of the sgACC and other cortical and subcortical regions (17,63,74) in impaired cognitive control, psychomotor retardation, and other symptom clusters in depression (75). In a study using both 1H-MRS and fMRI in patients with MDD, Glu levels in the mPFC associated with connectivity to subcortical regions (76), and Glx reductions in the sgACC predicted decreased functional connectivity between the sgACC and the anterior insula (77). Decreased Glu levels corresponded with decreased BOLD response to an emotional stimulus in patients with MDD with prominent anhedonia (78), suggesting that reduced glutamatergic neurotransmission and/or signaling may contribute to alterations in functional connectivity (79) at specific electrophysiologic oscillation frequencies relating to cognitive and limbic-related symptoms in depression.

**KETAMINE IN DEPRESSION**

Ketamine’s antidepressant effects were demonstrated over a decade ago in a double-blind, placebo-controlled clinical study of eight depressed patients randomly assigned to receive either a subanesthetic dose (0.5 mg/kg intravenously over 40 minutes) of ketamine or saline. Four of the eight patients (n = 7 completers) had an antidepressant response to ketamine (defined as a reduction of 50% or greater on the Hamilton Depression Rating Scale) (10). Subsequently, our group and others replicated intravenous ketamine’s antidepressant effects in both MDD and BD patients across single and repeated administrations under various study designs (8,9). The time course of the antidepressant response is characterized by an initial reduction in depressive symptoms within 2 hours, a maximal reduction in depressive symptoms within 24 hours, and a sustained response for up to 1 week after administration (9,11).

Ketamine’s effect on glutamatergic and GABAergic neurons has emerged from preclinical studies (80–83) (Figure 1). Ketamine antagonizes NMDA receptors on GABAergic interneurons and on postsynaptic neurons; the former disinhibits cortical glutamatergic neurons (83) and the latter increases synthesis of intracellular growth factors, such as brain-derived neurotrophic factor (81,82). In addition, by the kainate receptor, ketamine increases activity of mammalian target of rapamycin and other molecules responsible for neuroplasticity and synaptogenesis (81,82). A recent study examining both signaling pathways found that ketamine increased brain-derived neurotrophic factor by generating nitric oxide, leading to the stabilization of nitricergic Rheb, a small G protein that enhances mammalian target of rapamycin signaling (80). These findings have shifted our conceptualization of the pathophysiology and treatment of depression (17,84) and have encouraged the development of Glu-based treatments for depressive disorders (12,56,85,86).

**ANTIDEPRESSANT RESPONSE TO KETAMINE AND GLU/GABA NEUROTRANSMISSION**

To date, five 1H-MRS studies have examined Glu, Gln, Gix, and/or GABA levels, and one PET study used a mGluR5 ligand before and after intravenous ketamine infusion; all were conducted in healthy subjects (87–90) (Table 1). In a double-blind, placebo-controlled, crossover study of 10 men (n = 8 completers), elevated Gln levels were observed in the ACC 2 hours after infusion, correlating with psychotomimetic symptoms (87). In an open-label study of 13 men, significantly elevated Glu levels were observed in the ACC 35
### Table 1. Neural Correlates of Antidepressant Response to Ketamine

<table>
<thead>
<tr>
<th>Citation</th>
<th>Sample Size and Diagnostic Groups</th>
<th>Neuroimaging Method</th>
<th>Trial Design and Ketamine Dose</th>
<th>Significance and Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rowland et al., 2005 (87)</td>
<td>Healthy subjects N = 10 (10 men)</td>
<td>^1H-MRS, 4T MRI, 8-mL voxel placed in the ACC bilaterally; quantification of Glu, NAA, choline, creatine, Glu; images acquired before, during, and at end of loading dose before maintenance dose</td>
<td>Double-blind, placebo-controlled, single infusion; IV ketamine 0.27 mg/kg loading dose over 10 min, 0.0025 mg/kg per min thereafter for up to 2 hours until end</td>
<td>Increased Glu in the ACC associated with ketamine infusion</td>
</tr>
<tr>
<td>Taylor et al., 2012 (88)</td>
<td>Healthy subjects N = 17 (11 men, 6 women)</td>
<td>^1H-MRS, 3T MRI, 30 × 20 × 20 mm voxel placed in the ACC and mPFC; quantification of Glx, Glu, Gln; images acquired before, during, and after infusion</td>
<td>Double-blind, placebo-controlled, single infusion; IV ketamine 0.5 mg/kg over 40 min</td>
<td>No increase in Glu or Gln in the ACC or mPFC associated with ketamine infusion</td>
</tr>
<tr>
<td>Stone et al., 2012 (89)</td>
<td>Healthy subjects N = 13 (13 men)</td>
<td>^1H-MRS, 3T MRI, 30 × 30 × 30 mm voxel placed over the thalamus bilaterally and surrounding subcortical structures, 20 × 20 × 20 mm voxel placed over the ACC; quantification of Glu, Gln, GABA; images acquired before and after infusion at 25 min and 35 min</td>
<td>Open-label, single infusion; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Increased Glu in the ACC but no effect on ACC Glu + Gln, or subcortical GABA levels associated with ketamine infusion</td>
</tr>
<tr>
<td>Valentine et al., 2011 (84)</td>
<td>MDD subjects N = 10 (4 men, 6 women)</td>
<td>^1H-MRS, 3T MRI, 3.0 × 1.5 × 3.0 cm voxel placed in the OCC; quantification of Glu, Gln, GABA; images acquired before 3 hours after, and 48 hours after infusion</td>
<td>Single-blind, placebo-controlled, two infusions 1 week apart; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Improvement in depressive symptoms at 1 hours and for at least 7 days after ketamine infusion was not associated with baseline measures of, or changes in, occipital Glu, Gln, or GABA</td>
</tr>
<tr>
<td>Salvador et al., 2012 (65)</td>
<td>MDD subjects N = 14 (9 men, 5 women)</td>
<td>^1H-MRS, 3T MRI, 5 × 3 × 2 cm voxel placed in the DM/DA-PFC, 3 × 3 × 2 cm voxel placed in the vmPFC; quantification of Glu, Gln, Glx, GABA; images acquired 1–3 days before infusion</td>
<td>Open-label, single infusion; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Pretreatment GABA or Glu was not associated with a decrease in depressive symptoms in either of the two ROIs; pretreatment Glx/glutamate ratio in the DM/DA-PFC was negatively correlated with improvement in depressive symptoms</td>
</tr>
<tr>
<td>Milak et al., 2015 (93)</td>
<td>MDD subjects N = 11 (3 men, 8 women)</td>
<td>^1H-MRS, 3T MRI, 3.0 × 2.4 × 2.5 cm voxel placed in the mPFC and pgACC; quantification of Glu, Gln, Glx, GABA; images acquired before, during, and after infusion</td>
<td>Double-blind, placebo-controlled, two infusions 1 week apart; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Increased Gx and GABA in the mPFC associated with ketamine infusion</td>
</tr>
<tr>
<td>Scheidegger et al., 2012 (69)</td>
<td>Healthy subjects N = 19 (9 men, 10 women)</td>
<td>^3MRI, 3T MRI, SPBMs, seed ROIs in the CCM, the DMN, and affective networks, bilateral DLPFC, dACC, sgACC, and amygdala; images acquired before and 24 hours after infusion</td>
<td>Double-blind, placebo-controlled, crossover of two infusions 2 weeks apart; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Decreased functional connectivity of the DMN to a network of dorsal brain regions and to the sgACC and mPFC by the dACC associated with ketamine infusion</td>
</tr>
<tr>
<td>Grimm et al., 2015 (89)</td>
<td>Healthy subjects N = 24 (12 men, 12 women)</td>
<td>^3MRI, 3T MRI, SPBMs, seed ROIs in the DLPFC and hippocampus bilaterally; images acquired before and 20 min after infusion</td>
<td>Single-blind, placebo-controlled, crossover of 3 single infusions; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Increased functional connectivity between the DLPFC bilaterally and the left hippocampus associated with ketamine infusion</td>
</tr>
<tr>
<td>Carlson et al., 2013 (89)</td>
<td>MDD (TRD) subjects N = 26 (20 men, 6 women)</td>
<td>^18[Fr]-FDG, 3T MRI, SPMM, whole-brain and ROI analyses at ventral striatum and OFC; images acquired before and after</td>
<td>Open-label, single infusion; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Reduction in depressive symptoms associated with increased metabolism in STG/MTG and cerebellum, as well as decreased metabolism in ventral and medial loci within the STG/MTG, parahippocampal gyrus, inferior parietal cortex, and temporo-occipital cortex</td>
</tr>
<tr>
<td>Lally et al., 2015 (67)</td>
<td>MDD (TRD) subjects N = 20 (14 men, 6 women)</td>
<td>^18[Fr]-FDG, 3T MRI, SPMM, whole-brain and ROI analyses at ventral striatum and OFC; images acquired before and after</td>
<td>Open-label, single infusion; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Reduction in anhedonia was associated with increased metabolism in the hippocampus and dACC, as well as decreased metabolism in the inferior frontal gyrus and OFC</td>
</tr>
<tr>
<td>Li et al., 2016 (99)</td>
<td>MDD (TRD) subjects N = 48 (no sex breakdown given)</td>
<td>^18[Fr]-FDG, 3T MRI, SPMM, whole-brain and ROI analyses at PFC and amygdala; images acquired before and after</td>
<td>Double-blind, placebo-controlled, single infusion; group A: IV ketamine 0.5 mg/kg over 40 min; group B: IV ketamine 0.2 mg/kg over 40 min; group C: IV normal saline</td>
<td>Reduction of depressive symptoms was associated with increased metabolism in the PFC in groups A and B, but not group C; whole-brain analysis confirmed a group effect on the PFC (group A&gt;C; group B&gt;C); metabolic differences in the PFC predicted response at 40 and 240 min</td>
</tr>
<tr>
<td>Lally et al., 2014 (100)</td>
<td>BD-I and BD-II subjects N = 21 (8 men, 15 women) (all on lithium or valproic acid)</td>
<td>^18[Fr]-FDG, 3T MRI, SPMM, whole-brain and ROI analyses at ventral striatum and OFC; images acquired before and after</td>
<td>Double-blind, placebo-controlled, crossover of two infusions 2 weeks apart; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Reduction of depressive symptoms but not anhedonic symptoms was associated with increased metabolism in the ventral striatum; reduction in anhedonia was associated with increased metabolism in the dACC</td>
</tr>
<tr>
<td>Citation</td>
<td>Sample Size and Diagnostic Groups</td>
<td>Neuroimaging Method</td>
<td>Trial Design and Ketamine Dose</td>
<td>Significance and Findings</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Nugent et al., 2014</td>
<td>BD-I and BD-II subjects N = 21 (6 men, 15 women) (all on lithium or valproic acid)</td>
<td>PET, [18F]-FDG, 3T MRI, SPM5, whole-brain and ROI analyses at left and right amygdala, hippocampus, vIPFC, anteromedial PFC, DLPFC, ventral striatum, pgACC, sgACC, medial thalamus, dACC, lateral orbital cortex, superior temporal gyrus, frontal polar cortex, habenula, and anterior insula; images acquired before and at 120 min after infusion</td>
<td>Double-blind, placebo-controlled, crossover of two infusions 2 weeks apart; IV ketamine 0.5 mg/kg over 40 min</td>
<td>Reduction in depressive symptoms was associated with increased metabolism in the right ventral striatum, as well as reduced metabolism in left hippocampus in whole-brain analysis</td>
</tr>
<tr>
<td>Shaw et al., 2015</td>
<td>Healthy subjects N = 18 (18 men)</td>
<td>MEG acquired during visuomotor task before and after infusion, 3T MRI</td>
<td>Single-blind, placebo-controlled, crossover of two infusions; initial IV ketamine bolus of 0.25 mg/kg delivered over 1 min, followed by maintenance infusion at a rate of 0.25 mg/kg per hour</td>
<td>Increased beta amplitudes and decreased peak gamma frequency in the visual cortex, as well as amplified gamma-band amplitudes in motor and visual cortices were associated with ketamine infusion</td>
</tr>
<tr>
<td>Muthukumaraswamy et al., 2015</td>
<td>Healthy subjects N = 25 (25 men)</td>
<td>MEG acquired at rest and during visuomotor task before and during infusion, 3T MRI</td>
<td>Single-blind, placebo-controlled, crossover of two infusions; initial IV ketamine bolus of 0.25 mg/kg delivered over approximately 1 min, followed by maintenance infusion at a rate of 0.375 mg/kg per hour</td>
<td>Decreases in OCC, parietal, and ACC alpha power, increases in medial frontal theta power, and increases in parietal and cingulate cortex high gamma power in association with ketamine infusion; dynamic causal modeling showed that oscillatory changes were accompanied by temporally sustained reductions in frontoparietal effective connectivity</td>
</tr>
<tr>
<td>De Simoni et al., 2013</td>
<td>Healthy subjects N = 10 (10 men)</td>
<td>phfMRI, 3T MRI, BOLD signal, initiated 5 min before infusion, SPM5</td>
<td>Open-label, two infusions, IV ketamine (target plasma levels 50 ng/mL and 75 ng/mL)</td>
<td>Widespread changes present in ACC, mid-posterior cingulate and paracingulate cortices, hippocampal and parahippocampal regions, bilateral insula, DLPFC, vIPFC, thalamus, supplementary motor area, bilateral operculum, precuneus, and medial occipital lobes in association with ketamine infusion</td>
</tr>
<tr>
<td>Doyle et al., 2013</td>
<td>Healthy subjects N = 16 (16 men)</td>
<td>phfMRI, 3T MRI, BOLD signal, initiated at 15 min before infusion, SPM5</td>
<td>Double-blind, placebo-controlled, partial crossover design of four infusions, two with pretreatment risperidone or lamotrigine or placebo; IV ketamine (target plasma levels of 75 ng/mL) initially at 0.003 mg/kg for 1 min, then at approximately 0.31 mg/kg per hour</td>
<td>Lamotrigine and risperidone resulted in widespread attenuation of the ketamine-induced increases in signal, including the frontal and thalamic regions; a contrasting effect across both pretreatments was observed only in the sgPFC, in which ketamine reduced the signal</td>
</tr>
</tbody>
</table>

ACC, anterior cingulate cortex; BD, bipolar disorder; BOLD, blood–oxygen level dependent; CCN, cognitive control network; dACC, dorsal anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DM/DA-PFC, dorsomedial/dorsal anterolateral prefrontal cortex; DMN, default mode network; [18F]-FDG, [18]fluoro-deoxyglucose; fMRI, functional magnetic resonance; GABA, gamma-aminobutyric acid; Gln, glutamine; Glu, glutamate; Glx, combination of Glu and Gln; 1H-MRS, proton magnetic resonance spectroscopy; IV, intravenous; MDD, major depressive disorder; MEG, magnetoencephalography; mPFC, medial prefrontal cortex; MRI, magnetic resonance imaging; NAA, N-acetylaspartate; OCC, occipital cortex; OFC, orbitofrontal cortex; PET, positron emission tomography; PFC, prefrontal cortex; pgACC, perigenual anterior cingulate cortex; phfMRI, pharmacologic functional magnetic resonance; ROI, region of interest; sgACC, subgenual anterior cingulate cortex; sgPFC, subgenual prefrontal cortex; SPM, statistical parametric mapping; STG/MTG, superior and middle temporal gyri; TRD, treatment-resistant depression; vIPFC, ventrolateral prefrontal cortex; vmPFC, ventromedial prefrontal cortex.
minutes after infusion that did not correlate with psychotomimetic symptoms (89). A third double-blind, placebo-controlled, parallel group design study of 17 men (ketamine: \(n = 8\); placebo: \(n = 9\)) found that ketamine administration was not associated with changes in Glx, Glu, or GABA levels in the mPFC/ACC 40 minutes after infusion (88). Inconsistent results in small samples make it challenging to draw definitive conclusions about ketamine-induced amino acid neurotransmitter changes in healthy volunteers. In addition, one study (87) did not measure Glu directly, and scan quality was too poor in another study (89) to measure Gln levels. Nevertheless, consistent with the “glutamate surge” hypothesis, Glu levels increased during ketamine infusion, leading to psychotomimetic effects, with a subsequent decrease of Glu to baseline levels after infusion ceased. In support of this hypothesis, DeLorenzo et al. (40) examined PET scans before and after infusion with an mGlur5 ligand to measure the degree of ketamine binding to the mGlur5 receptor in 10 healthy control subjects who received intravenous ketamine. Reduced mGlur5 ligand (or increased ketamine) binding was found in the ACC, mPFC, orbital PFC, ventral striatum, parietal lobe, dorsal putamen, dorsal caudate, amygdala, and hippocampus (90). The ligand used in this study (ABP-688) is an allosteric modulator; therefore, it may not be a valid method of measuring Glu release. Although basimglurant (RO4917523, RG7090), a negative allosteric modulator at mGlur5, has shown promise as an adjuvant medication to traditional antidepressant medications (91) in one study, a significant reduction in the Montgomery-Åsberg Depression Rating Scale was found in the self-reported rather than clinician-administered Montgomery Asberg Depression Rating Scale; therefore, replication is necessary to support its antidepressant efficacy.

Three \(^1\)H-MRS studies examined ketamine-related changes in Glu, Glx, and/or GABA in patients with MDD (92–94) (Table 1); two uncovered no neurochemical signature associated with antidepressant response to ketamine (93,94). The third study observed improved depressive symptoms in 14 unmedicated, treatment-resistant patients with MDD in association with increased pretreatment Glx/Glu ratio in the dorsomedial PFC/dorsal anterolateral PFC. Pretreatment measures of GABA or Glu did not correlate with reduction in depressive symptoms in either of these two regions of interest (\(p > .1\)) (92). In another study of 11 unmedicated patients with MDD, no association was observed between antidepressant response to ketamine and Glx or GABA levels in the mPFC before, during, or after ketamine infusion (93). Interestingly, in this study, ketamine was associated with increased Glx/water and GABA/water ratios, indicating target engagement and suggesting that ketamine transiently increases excitatory and inhibitory neurotransmission. Finally, in a single-blind study of 10 patients with MDD, ketamine was associated with reduced depressive symptoms at 1 hour to 7 days after infusion; however, antidepressant efficacy was not associated with baseline levels or change in any amino acid neurotransmitter within the OCC (94). Therefore, it is unclear whether amino acid neurometabolite levels or their ratios can help predict antidepressant response to ketamine owing to inconsistent results in small samples across different imaging platforms.

**KETAMINE AND FUNCTIONAL NEURAL CIRCUITRY IN DEPRESSION**

Increased pretreatment neural activity in the rostral ACC associates with antidepressant response across different pharmacologic, electrophysiological, and behavioral interventions (74), suggesting that a common neurobiological signature may be associated with antidepressant response to treatment. In healthy subjects, functional connectivity between the rostral ACC and mPFC increased acutely (95) and decreased 24 hours after ketamine infusion (96). Furthermore, with the use of PET imaging methods, ketamine associated with increased glucose metabolism in the dorsal ACC (dACC) (97), altered glucose metabolism in PFC regions (97–99) in MDD, and increased glucose metabolism in the dACC and putamen in patients with BD (100). Our group has shown that sgACC hypermetabolism predicted response to ketamine in patients with BD (101). Taken together, the evidence suggests that specific activation patterns in the sgACC and dACC lead to disrupted functional engagement of PFC regions that is partly modifiable in patients with depression through glutamatergic interventions. This adds to the substantial and mounting evidence not only that the ACC is a key hub connecting limbic dysfunction with clinical symptoms in MDD, but also that its functional response may correlate with ketamine’s antidepressant efficacy.

Excitatory/inhibitory neurotransmitter imbalances may be inferred through specific electrophysiological measures. For example, interactions between superficial excitatory pyramidal cells and inhibitory GABAergic interneurons are attributed to oscillations in the gamma-frequency band as measured by MEG (83,102,103). Increases in gamma-band power (104,105), reduced coupling of spike-rate and local field potential power within the gamma band (105), and disruptions in neuronal plasticity within prefrontal–hippocampal circuits (106) have been associated with NMDA receptor blockade with ketamine in the rodent neocortex. Similarly, in humans, subanesthetic-dose ketamine infusion associates with increased gamma-band amplitudes in motor and visual cortices (102) and decreased peak gamma frequency in the visual cortex (107). Given the correlation between gamma-band oscillations and BOLD connectivity in both rodents (108) and humans (109), ketamine may be associated with abnormalities in functional connectivity and disruptions in neuronal plasticity, particularly in circuits interconnecting the hippocampus and PFC (108,110). Glu levels in the posterior cingulate cortex strongly correlate with connectivity in the DMN (111), suggesting that Glu alterations by ketamine administration may give rise to alterations in brain function at rest (i.e., non-task) as well as during a task. Finally, a MEG study in healthy volunteers (\(N = 25\) men) found that subanesthetic-dose ketamine increased anterior theta and gamma power but decreased posterior theta, delta, and alpha power; these changes were sustained for up to 50 minutes after ketamine infusion (i.e., after the resolution of perceptual distortions) (112). The investigators reported frontoparietal connectivity changes, with ketamine reducing NMDA- and AMPA-mediated frontoparietal connectivity. If replicated, the antidepressant effects of ketamine may depend on acute and prolonged changes in MEG spectral
power, as well as in electrophysiological synchrony in frontoparietal circuitry. The extent to which gamma-band changes measured by MEG reflect altered glutamatergic neurotransmission and/or signaling in association with ketamine administration is unclear. Furthermore, given that current studies are limited to healthy subjects (Table 1), it is not known whether ketamine-related electrophysiological changes are similar in depressed patients.

KETAMINE AS A FUNCTIONAL NEUROCIRCUITRY MODULATOR: FUTURE DIRECTIONS

In depressed patients, evidence from neurochemical studies of MDD and BD suggests that alterations in Glu-related excitatory neurotransmission exist in a subset of patients. Although evidence of isolated abnormalities in GABA-related inhibitory neurotransmission in depression has been less clear, a reduction in efficient energy metabolism in glutamatergic neurons may lead to an imbalance of Glu over GABA neurotransmission that manifests as network connectivity perturbations in BD and MDD. Moreover, given the small number of existing clinical studies with low-powered samples of patients with MDD, it is unclear how ketamine’s antidepressant efficacy is associated with specific Glu and/or GABA levels. Further studies are needed at higher magnetic field strength with attention to specific regions of interest such as the sgACC, dACC, frontoparietal cortices, mPFC, and limbic areas (Figure 2). In addition, resting-state MEG studies—particularly those focused on beta- and gamma-band activity—may reveal connectivity changes that correlate with and/or predict ketamine’s antidepressant response.

Evidence of large variations in Glu levels during and after ketamine infusion in healthy and depressed subjects warrants examination of changes in Glu/GABA neurochemistry in conjunction with functional neuroimaging before, during, and after ketamine infusion (87–89,92–94). Pharmacodynamic fMRI is a functional imaging technique that measures brain response during infusion of pharmacologic agents, thus providing early and longitudinal measures of drug action in the brain (113). Pharmacodynamic fMRI studies conducted in healthy volunteers have established test-retest reliability (114) and specificity (115) in association with ketamine infusions (Table 1), further supporting that such an approach in future ketamine studies may help predict those who may experience an antidepressant response.

Finally, identifying reliable diagnostic and treatment response biomarkers in MDD has been a challenge, given the clinical heterogeneity of this disorder and the wide variability of treatment response (17,84,116). Neuroendocrine, neurochemical, and neurophysiological assays in the search for MDD biomarkers have been replicated in some, but not all, translational studies (117–120). Moreover, the consensus within the field has been that neuroimaging techniques, in conjunction with other illness biomarkers, may be required to diagnose and treat psychiatric disorders (119–121). A combinatorial approach of diverse techniques and methods (122) will be required to identify underlying neural system abnormalities that are unique to subgroups of patients with MDD and/or correlate with antidepressant response.

Figure 2. Proposed regions of interest to identify alterations in glutamate/gamma-aminobutyric acid and abnormalities in functional connectivity. Sagittal, axial, and coronal viewpoints showing the medial prefrontal cortex in yellow. Sagittal viewpoint showing the frontoparietal cortical region in red and the dorsal anterior cingulate cortex in blue. Sagittal and coronal viewpoints showing the subgenual anterior cingulate cortex in green. Axial viewpoint showing the dorsolateral prefrontal cortex in purple. Hippocampus and amygdala not shown in figure. Modified with permission (55).
Glutamate and GABA in Depression

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (Grant Nos. IRP-NIMH-NIH and ZIA MH002657).

We thank the 7SE research unit and staff for their support, and Ms. Iolina Henter for invaluable editorial assistance.

MSL, MJN, EDB, MP, LTP, and AN report no biomedical financial interests or potential conflicts of interest. CAZ is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. CAZ has assigned his rights in the patent to the US government but will share a percentage of any royalties that may be received by the government.

ARTICLE INFORMATION

From the Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.

Address correspondence to Marc S. Lener, M.D., National Institute of Mental Health, 10 Center Dr, Building 10/CRC, Room 7-5545, Bethesda, MD 20892; E-mail: marc.lener@nih.gov.

Received Feb 23, 2016; revised May 4, 2016; accepted May 5, 2016.

REFERENCES

Glutamate and GABA in Depression


Glutamate and GABA in Depression


